Company: DERM
Filing Date: 2025-08-28
Form Type: 8-K
Source: 0001104659-25-084879
Chunk: 1

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 8-K
Item: Item 1.01
Chunk 1
---
 description of the Sales Agreement
does not purport to be complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which
is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the legal opinion of
Troutman Pepper Locke LLP relating to the legality of the issuance of the Shares in the offering is attached as Exhibit 5.1 hereto.

This Current Report on Form 8-K shall not constitute
an offer to sell or the solicitation of an offer to buy any Shares, nor shall there be any sale of such Shares in any state in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

Item 1.02 Termination of a Material Definitive
Agreement

As
previously disclosed, on December 30, 2022 the Company entered into that certain At Market Issuance Sales Agreement (the “ Original
Sales Agreement”) with B. Riley pursuant to which the Company could offer and sell, from time to time at its sole discretion, 4,900,000
shares of its common stock, through or to B. Riley, in sales deemed to be an “at the market offering” as defined in
Rule 415(a)(4) under the Securities Act. Effective as of August 28, 2025, the Company terminated the Original Sales Agreement.

Following the termination of the Original Sales
Agreement, the Company may not offer or sell any additional shares of common stock under the Original Sales Agreement. From December 30,
2022 to August 28, 2025, the Company sold 4,121,318 shares of common stock pursuant to the Original Sales Agreement.

The foregoing description of the Original Sales
Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Original Sales Agreement,
a copy of which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on January 3, 2023, and
incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibits are furnished herewith:

  Exhibit      Description                                                                                                                          
   Number                                                                                                                                           
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────